Lancashire and South Cumbria
Formulary
Formulary
4 Central nervous system
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
04-10-03 Opioid substitution therapy
| Buprenorphine and Naloxone Suboxone® |
|
Formulary
|
| Sublingual tablets (SuboxoneŽ) 2mg/500micrograms, 8mg/2mg tablets |
|
Links
MHRA Drug Safety Update Jan 2020: E-cigarette use or vaping: reporting suspected adverse reactions, including lung injury- NICE CG52: Drug misuse in over 16s: opioid detoxification
- NICE NG209: Tobacco: preventing uptake, promoting quitting and treating dependence
- NICE TA114: Methadone and buprenorphine for the management of opioid dependence
- NICE TA114: Methadone and buprenorphine for the management of opioid dependence
- NICE TA115: Drug misuse - naltrexone
- NICE TA115: Naltrexone for the management of opioid dependence